ABX464 (OBEFAZIMOD) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INTERIM 48-WEEK SAFETY AND EFFICACY ANALYSIS FROM AN ONGOING 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY

Severine Vermeire  1     Bruce E. Sands  2     Sophie Biguenet  3     Hartmut Ehrlich  3     Paul GINESTE  3     Josianne Nitcheu  3     William Sandborn  4    
1 University Hospitals Leuven, Leuven, Belgium
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 Abivax, Paris, France
4 University of California San Diego, San Diego, United States

Session
Clinical trials in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)

Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing